TTM
−$107.23M
YoY change
-22.0%
5Y CAGR
—
Peak year (2019)
−$14.10M
Cumulative net income
−$611.63M
Net Income history chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: −$101.59M
Net Income growth chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: -22.0%
Net Income history table for Tango Therapeutics (TNGX) from 2019 to 2025
| 2025 | −$101.59M | -22.0% | +$28.71M | ||
| 2024 | −$130.30M | +28.1% | −$28.56M | ||
| 2023 | −$101.74M | -5.9% | +$6.43M | ||
| 2022 | −$108.18M | +85.8% | −$49.94M | ||
| 2021 | −$58.23M | +12.1% | −$6.26M | ||
| 2020 | −$51.97M | +268.7% | −$37.88M | ||
| 2019 | −$14.10M | — | — |
- 2025−$101.59M-22.0%
- 2024−$130.30M+28.1%
- 2023−$101.74M-5.9%
- 2022−$108.18M+85.8%
- 2021−$58.23M+12.1%
- 2020−$51.97M+268.7%
- 2019−$14.10M—
Net Income values are taken from Tango Therapeutics's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Net Income at Tango Therapeutics (TNGX)
According to Tango Therapeutics's latest reported financial statements, the company's current net income (TTM) is −$107.23M. Net income is the bottom-line profit after all expenses — cost of goods sold, operating expenses, interest, and taxes — are subtracted from revenue. It is the figure used to compute earnings per share (EPS) and is the residual available to shareholders.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Tango Therapeutics (TNGX) reported net income of −$101.59M – declined 22.0% year-over-year.
−$14.10M stands as the all-time-high annual net income, posted in 2019, against a low of −$130.30M during 2024.
Tango Therapeutics Net Income by Year
Tango Therapeutics Net Income 2025: −$101.59M
Tango Therapeutics posted net income of −$101.59M in 2025, declined 22.0% below 2024.
Tango Therapeutics Net Income 2024: −$130.30M
In 2024, Tango Therapeutics reported net income of −$130.30M, grew 28.1% from 2023. This figure represents the lowest annual value in the available history.
Tango Therapeutics Net Income 2023: −$101.74M
Tango Therapeutics net income in 2023 was −$101.74M, declined 5.9% below 2022.
Tango Therapeutics Net Income 2022: −$108.18M
2022's net income for Tango Therapeutics came in at −$108.18M, surged 85.8% from 2021.
Tango Therapeutics Net Income 2021: −$58.23M
Tango Therapeutics net income in 2021 was −$58.23M.
See more financial history for Tango Therapeutics (TNGX).
Sector peers by Net Income
Healthcare peers of Tango Therapeutics (TNGX), ranked by their latest net income
| $26.80B | |
| $20.64B | |
| $18.25B | |
| $15.97B | |
| $12.06B | |
| $10.26B | |
| $7.71B | |
| $4.23B |
- $26.80B
- $20.64B
- $18.25B
- $15.97B
- $12.06B
- $10.26B
- $7.71B
- $4.23B
Frequently asked questions
Tango Therapeutics (TNGX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation